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Losartan modulation on NOS isoforms and COX-2 expression
in early renal fibrogenesis in unilateral obstruction.
Background. Angiotensin II plays a central role in the ini-
tiation of renal fibrogenesis at a very early stage leading to
a rapid progression in unilateral ureteral obstruction (UUO).
We examined the effect of an angiotensin II receptor inhibitor
(AT1) losartan, independent from its effects on blood pressure,
on nitric oxide synthase (NOS) isoforms and cyclooxygenase-2
(COX-2) expression and the significance of this interaction on
interstitial fibrosis in UUO.
Methods. Rats underwent UUO for 24 hours or control sham
operation after been treated with losartan in the drinking water
at 10 mg/kg/day for 15 days. AT1 receptor binding and distri-
bution was determined by in situ autoradiographic study. Re-
nal fibrosis was evaluated through the relative volume of the
tubulointerstitium (Vv) measured by an image analyzer, and
transforming growth factor-b (TGF-b) at mRNA levels. NOS
activity, expression of NOS isoforms by reverse transcription-
polymerase chain reaction (RT-PCR) assay and COX-2 protein
expression, were determined.
Results. After administration of a nonhypotensive dose of
losartan prevention of renal fibrogenesis was demonstrated in
obstructed kidneys by means of Vv values and TGF-b mRNA
expression near controls. Decreased AT1 receptor binding den-
sity was observed in cortex and inner stripe of the outer medulla
of nontreated obstructed kidney compared to control, whereas
no differences were observed in ipsilateral UUO related to ob-
structed kidney–treated group.
The increased inducible NOS (iNOS) activity and expres-
sion of obstructed kidney medulla, increased neuronal NOS
(nNOS), and endothelial NOS (eNOS) isoforms expression and
COX-2 protein expression in obstructed kidney cortex showed
down-regulation of iNOS, nNOS, and COX-2 with persistent
levels of eNOS after losartan administration.
Conclusion. These results allowed us to infer an intersti-
tial fibrogenesis prevention independent action of losartan, in-
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volving NOS isoforms and COX-2, in unilateral obstructive
nephropathy.
The pathologic mechanism underlying chronic ob-
structive nephropathy is not completely elucidated, al-
though the fibrogenic process clearly plays a critical
role in ultimately leading to permanent loss of the nor-
mal structural and functional integrity of the kidney [1,
2]. Unlike most forms of chronic renal diseases, often
taking months to establish fibrotic lesions, obstructive
nephropathy induced by complete, continous ureteral ob-
struction, is an exceptionally aggressive form of tubu-
lointerstitial fibrosis [3]. Renal fibrogenesis initiates at a
very early stage after ureteral obstruction and progresses
rapidly [4]. Angiotensin II plays a central role in the
initiation and progression of renal disease by autocrine,
paracrine, intercrine, and endocrine pathways. Intrarenal
concentrations of angiotensin II increase rapidly after the
onset of ureteral obstruction in the ligated obstructed kid-
ney. Increased plasma renin activity and renin content,
angiotensin-converting enzyme (ACE) and angiotensin
II concentration in the experimental kidney are asso-
ciated with unilateral ureteral obstruction (UUO) [5].
Angiotensin II has been shown to mediate overexpres-
sion of transforming growth factor-b (TGF-b) gene, a
major cytokine in the regulation of extracellular matrix
(ECM) protein synthesis [6]. Significant blunting of this
process with ameliorating tubulointestitial fibrosis by an
ACE inhibitor and angiotensin II receptor antagonist
(AT1) has been previously reported [7, 8]. In addition,
angiotensin II has been shown to up-regulate the ex-
pression of a cytokine, tumor necrosis factor-a (TNF-a)
[9]. Exposure of kidney epithelial cells from proximal
tubule and inner medullary collecting duct (IMCD)
to TNF-a increases the level of inducible nitric oxide
synthase (iNOS) mRNA [10]. Stimulation of NOS ex-
pression by angiotensin II has also been shown in en-
dothelial cells [11]. Evidence also suggests that iNOS may
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be expressed under basal conditions in some tissues. Basal
expression of iNOS mRNA has been detected in several
normal tissues from adult rats [12]. The constitutive NOS
isozymes are constantly expressed but are inactive un-
til intracellular Ca2+ levels increase sufficiently to main-
tain calmodulin binding [13]. Notwithstanding neuronal
NOS (nNOS) and endothelial NOS (eNOS) are classi-
fied as constitutive enzymes, the increased renal vascu-
lar resistance, that enhances shear stress and hypoxia,
is involved in the constitutive NOS (cNOS) isoform ex-
pression in obstruction [14]. Previous studies have shown
that endogenous levels of nitric oxide can influence the
formation of prostaglandins. Prostaglandins and nitric
oxide are important mediators of inflammation. Stimu-
lation of a wide variety of cell types with cytokines and
other messengers results in a rapid induction of iNOS
and prostaglandins. In cells expressing both inducible
prostaglandin endoperoxide synthase (PGHS) and NOS,
nitric oxide stimulates prostaglandin production [15].
Regulation of cyclooxygenase-2 (COX-2) gene expres-
sion by nitric oxide has been demonstrated in mesangial
cells in which nitric oxide donors up-regulated interleukin
(IL)-1B–driven COX-2 mRNA and protein expression
[16].
A target for intervention in the fibrotic and apoptotic
processes in obstruction may be the complex interaction
of nitric oxide and TGF-b , induced by angiotensin II, in
renal epithelial cells [17]. Recently, prostaglandins have
been reported to alter ECM formation by mesangial cells.
In addition, a significant reduction of tissue TGF-b by the
inhibition of COX-2 has been shown [18].
This study examines the AT1 angiotensin II receptor
inhibition independent from its effects on blood pres-
sure, on NOS isoforms and COX-2 expression, and the
significance of this interaction on interstitial fibrosis in
UUO.
METHODS
Experiments were performed in female Wistar Kyoto
rats with an average body weight of 180 g (N = 108). The
animals were fed a standard laboratory diet and water ad
libitum. Animals were randomly assigned to the group
that received a specific inhibitor of the AT1 angiotensin II
receptor [19]. Losartan was administered in the drinking
water at 10 mg/kg/day for 15 days, and the other group
received plain water. Blood pressure was measured in
both groups before and after pharmacology treatment by
means of an Pletismografic Grass method (Quincy, MA,
USA). After these 2 weeks of losartan administration,
UUO was performed in half of rats of the losartan group
and in half of the water drinking group. Four groups were
formed, on each of the four groups 27 rats were included.
Group I included UUO rats without losartan administra-
tion, group II were control rats and received no losartan
administration; group III were UUO rats given oral losar-
tan administration for 15 days; and group IV were control
rats given losartan administration for 15 days.
Animal model of UUO
Urinary tract obstruction of the left kidney of female
Wistar Kyoto rats was performed as follows. Animals
were first anesthetized with pentobarbital 50 mg/kg body
weight intraperitoneally, using an aseptic technique, and
a midline abdominal incision was performed. The left
ureter was completly ligated with 4.0 silk at the upper
two thirds of the ureter. The abdominal incision was
closed with sutures, the rats were allowed to awaken and
were given free access to water and food. The control
group underwent a fictitious surgery. Ureteral obstruc-
tion was confirmed by observation of dilation of the pelvis
and proximal ureter and collapse of the distal ureter at
24 hours. Twenty-four hours later the obstruction was re-
leased by removal of the ligature. Clearance studies were
done on the day of the obstruction release. Rats (N =
6 on each group) were anesthetized and catheters were
placed in the femoral vein and artery and both ureters.
In rats from groups I and III, the release of ureteral ob-
struction was performed by cannulating the obstructed
ureter proximal to the ligature placed 24 hours earlier.
Rats were placed in plexiglass holders and a period of
1 hour was allowed for recovery from anesthesia. Then
a priming dose of inulin (Sigma Chemical Co., St. Louis,
MO, USA) dissolved in normal saline (0.6 to 1 mL) was
infused over 3 minutes. It was followed by a sustaining in-
fusion of inulin in normal saline given at a rate of 40 lL/
min designed to result in serum concentration of inulin
of 75 to 100 mg/dL.Two hours after the infusion was
started, three consecutive collections of urine of 30 min-
utes each was obtained. Urine volume was determined
by weighing the urine collected in previously weighed
tubes. Blood was drawn at the beginning, midpoint, and
end of each clearance period, collected in heparinized
microhematocrit capillary tubes. Mean arterial pressure
(MAP) was determined through the left femoral artery
catheter connected to a manometer.Two successive read-
ings were obtained. After completing the clearance stud-
ies, the animals were anesthetized and perfusion through
the aorta with cold phosphate-buffered saline (PBS) was
performed. Kidneys were rapidly removed and sliced on
a cold glass plate.
For histologic studies, kidney sections were fixed in
10% phosphate-buffered formalin (pH = 7.1) for 24
to 48 hours before embedded in paraffin and serially
sectioned (5 lm) on a microtome (Leica, Nussloch,
Germany). Paraffin sections were subjected to stain-
ing with hematoxylin-eosin and Masson trichromic.
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Kidney sections were treated sequentially with Weigert’s
iron hematoxylin solution × 10 minutes, Biebrich
scarlet–acid fuchsin × 2 minutes, phosphotungstic
acid/phosphomolybdic acid × 10 minutes, and aniline
blue × 5 minutes for Masson trichromic staining. Tissue
was destained in 1% acetic acid × 2 minutes, dehydrated
through graded ethanol to xylene, and mounted for ex-
amination by light microscopy [20].
Morphometric evaluation of interstitial fibrosis
For all morphologic evaluations the observer was naive
to the origin of the histologic sections. A standard point
counting method [21, 22] was used to quantitate the vol-
ume of the renal interstitium. The relative volume (Vv)
of the renal cortical interstitium was determined in sec-
tions by using the Masson trichrome method to stain col-
lagen fibers. Blue-stained interstitial fibrotic areas were
assessed by using an image analyzer (Image Pro-Plus 4.0;
Media Cybernetics, Silver Spring, MD, USA). Ten con-
secutive fields were randomly selected in renal cortex and
medulla and were evaluated at 400 × on a 10 × 10 grid-
imprinted reticule. All points not counted within tubular
cells, lumen, glomeruli, or vascular space were consid-
ered interstitial. This fraction represented the relative
interstitial volume. The number of grid points contain-
ing blue collagen staining in the interstitium was divided
by the total number of points in the fields (1000) to ob-
tain the percentage fractional area of interstitial collagen
deposition.
Results were expressed as percentage of the measured
area, which represented the interstitial space and was de-
termined as the relative volume (Vv) of the interstitium.
Tubular diameter in renal cortex and medulla
Tubule atrophy has been previously determined by
measuring tubule diameter, which would be an index of
all apoptotic cell loss - atrophic tubules were identified
by their thickness [22].
To evaluate if atrophy affected 24-hour kidney obstruc-
tion tubules, measurement of tubule diameter on kidney
sections stained with Masson trichromic was performed.
The diameter of the tubules per field of a 40 × objec-
tive was determined in the same 10 fields of cortex and
medulla per kidney section in which the relative volume
(Vv) of the interstitium was measured. Tubular diameter
was assessed by using an image analyzer (Image Pro-Plus
4.0).
Preparation of kidneys for NOS activity and
RNA extraction
The kidneys were perfused from the abdominal aorta
with 25 mL of cold PBS solution to rinse all the blood.
For the determination of NOS activity, a protocol for ho-
mogenates was performed.
Slices from kidneys (N = 10 in each group) were done
and renal cortex and medulla were removed under a
stereomicroscope. After weighing both the cortex and
the medulla, they were immediately frozen on dry ice.
Later, tissues were homogenized by using a glass micro-
homogenator (Lighting Model Mixer-Volts 100) (Mixing
Equipment Co., Inc., Rochester, NY, USA.) in a cool so-
lution (10 mg tissue/100 lL solution) containing Hepes-
Tris10 mmol/L, sacarose 0.32 mol/L, dithiothreitol (DTT)
1 mmol/L, soybean trypsin inhibitor 1 mg/100 mL, and
trasylol 2.5 lg/mL to pH = 7.40. Cortex and medulla ho-
mogenates of each kidney were used for the measurement
of inducible and constitutive isoforms of NOS enzyme.
Measurement of NOS activity
NOS activity was quantified by measuring the conver-
sion of L-[3H] arginine to L-[3H] citrulline in the presence
of saturating concentrations of the enzyme’s cofactors as
it was described before [23] with brief modifications.
Homogenates from renal cortex and medulla were
centrifugated at 3000 rpm at 4◦C for 10 minutes. A
40 lL aliquot of each supernantant fraction was incubated
with 3 mmol/L CaCl2, 1 mmol/L b-nicotinamide ade-
nine dinucleotide reduced form (NADPH), 25 lmol/L
flavin adenine dinucleotide (FAD), 1.25 lg/mL calmod-
ulin, 10 lmol/L tetrahydrobiopterin, and [3H] arginine
(approximately 300,000 cpm, 6.8 Ci/mL) in 20 mmol/L
Hepes buffer, pH = 7.40, at 37◦C for 30 minutes.
Calcium/calmodulin-independent NOS activity was mea-
sured by using the same buffer and cofactors, with-
out calcium and calmodulin, after the addition of
0.5 mmol/L ethylenediaminetetraacetic acid (EDTA).
Parallel reactions were analyzed in the presence of NG-
nitro-L-arginine methyl ester (L-NAME) 20 mmol/L, an
inhibitor of inducible and constitutive isoforms NOS in
renal cortex and medulla of control kidneys. The reac-
tion was stopped by the addition of L-NAME 20 mmol/L
Hepes buffer (100 lL) at 4◦C. The total volume (210 lL)
was applied to a Dowex 50W-X8, 100 to 200 mesh column
(volume 0.6 mL) that had been pre-equilibrated with 20
mmol/L Hepes (pH = 7.40) and saturated with 20 mmol/L
of cold citrulline. [3H] citrulline was eluted with 200 lL
of deionized water and radioactivity was quantified by
scintillation counting (Wallac, LK Beta Rack, Finland).
Blanks included 50 lL of homogenate buffer plus 60 lL
of reaction buffer without or with calcium/calmodulin to
measure iNOS and cNOS respectively. The results are ex-
pressed as fmol [3H] citrulline/min incubation/lg protein.
Protein concentrations were measured according to
Bradford [24] by using Bio-Rad reagent (Bio-Rad Lab-
oratories, Hercules, CA, USA). Bovine serum albumin
(BSA) was used as standard (1 mg/mL).
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RNA isolation, reverse transcription-polymerase
chain reaction (RT-PCR), and semiquantification
for NOS isoforms
For RNA extraction, kidneys (N = 6 in each group)
were rapidly removed and cortex and medulla dissected
immediately. Total RNA was prepared by using Trizol
reagent (from Gibco, BRL, Life Technologies, Gaithers-
burg, MD, USA). The total RNA was dissolved in
RNAse-free water (Promega, Madison, WI, USA) and
quantitated by ultraviolet spectrophotometry at 260 nm
and 280 nm. RNA with an optical density (OD) 260/OD
280 ratio between 1.7 to 1.9 was used for cDNA synthesis.
Three to five micrograms of RNA have been denatu-
rated in the presence of 0.5 mg/50mL oligo (dT)15 primer
and 40 U recombinant ribonuclease inhibitor (RNasin)
(Promega). RT was performed in the presence of mix-
ture by using 200 U Reverse Transcriptase Moloney-
murine leukemia virus (M-MLV) RT in reaction buffer
(Promega), 0.5 mmol/L deoxynucleoside triphosphate
(dNTP) each, and incubating 60 minutes at 37◦C. The
cDNA (15 lL) was amplified by PCR. Each sample was
measured for iNOS, nNOS, eNOS, and b-actin cDNA
in separate tubes using 50 pmol specific primers. The up-
stream and downstream primers for iNOS were 5′-GCAT
GGACCAGTATAAGGCAAGCA-3′ and 5′-GCTTCT
GGTCGATGTCATGAGCAA-3′, respectively. These
yield a single band corresponding to a 222 bp fragment.
Analysis of the sequence revealed that it was identical to
position 1693–1915 in mouse macrophage iNOS cDNA
[25].The upstream and downstream primers for nNOS
were 5′-GAACCCCCAAGACCATCC-3′ and 3′-GGC
TTTGCTCCCACAGTT-5′, respectively, which yield a
single band corresponding to a 308 bp cDNA frag-
ment [26]. The upstream and downstream primers for
eNOS (325 bp) were 5′-CTACAGAGCAGCAAATCC
ACCCG-3′ and 5′-AGCAGTCGAAGGAGGCGAGG
ACTAG-3′, respectively. These primers were designed
by Dr. Marı´a Ru¨ttler by using the PC/Gene (the nucleic
acid and protein sequence analysis software system from
the University of Geneva/Switzerland IntelliGenetics, re-
lease 6.85/1995, serial number IGI 3481).
The upstream and downstream primers for b-
actin was 5′-TGGAGAAGAGCTATGAGCTGCCTG-
3′ and 5′-GTGCCACCAGACCAGCACTGTGTTG-3′,
respectively, which yield a single band corresponding to
a 201 bp cDNA fragment. Amplification of a fragment of
b-actin was done so as to evaluate nonspecific effects of
the experimental conditions and to semiquantitate NOS
isoforms expression PCR was performed by incubating
15 lL of sample cDNA with 50 mmol/L KCl Tris-ClH,
0.1% gelatin, 1.5 mmol/L MgCl2, 2 U Taq polymerase,
100 pmol of b-actin or iNOS primers in 50 lL final vol-
ume PCR reaction was carried out for 30 cycles for iNOS,
nNOS, and b-actin (denaturation 1 minute at 94◦C, an-
nealing 1 minute at 55◦C and 2 minutes extension step at
72◦C, followed by a final extension step of 3 minutes at
72◦C).
RT-PCR for TGF-b
The mixture of total RNA 3 to 5 lg/10 lL RNAase-
free water, and 0.5 mg/50mL oligo (dT) was incubated
at 65◦C for 10 minutes to denature the secondary struc-
ture and chilled in ice immediately. The resulting mix-
ture was incubated at 42◦C for 1 hour adding 200 U
of Reverse Transcriptase M-MLV RT in reaction buffer
(Promega), heated at 94◦C for 5 minutes and chilled on
ice. The cDNA (15 lL) was amplified by PCR. Ampli-
fication was done in a total volume of 50 lL contain-
ing PCR buffer (50 mmol/L KCl, 10 mmol/L Tris-HCl, 2
mmol/L MgCl2, 200 lmol/L dNTP, 1.25 U Taq DNA poly-
merase, 100 pmol of b-actin or 50 pmol of oligonucleotide
primers for TGF-b . The TGF-b primers were designed
from the sequence of the rat gene sense 5′-GGACTAC
TACGCCAAAGAAG-3′ (bp 715–734) and antisense
5-TCAAAAGACAGCCACTCAGG-3′ (bp 989–1008).
The anticipated PCR product was 294 bp in length [27].
To quantitate PCR products and to confirm the in-
tegrity of RNA, we coamplified a housekeeping gene,
b-actin in companion tubes. PCR was performed with
a DNA Thermal Cycler (Minicycler MJ Research,
Beverly, MA, USA) with the following program: 95◦C
for 1 minute (denaturing), 54◦C for 1 minute (annealing),
and the extension phase at 72◦C for 1 minute. The reac-
tion was followed by a final elongation step at 72◦C for
7 minutes. Controls with no added RT were run in paral-
lel to rule out genomic contamination. Amplification was
carried out at 30 cycles for TGF-b and for b-actin.
Relative quantitation of mRNA
To 15 lL of the final product, PCR was electrophoresed
by using 1.5% agarose gel in Tris-boric acid-EDTA (TBE)
buffer. Gels were stained with 1 mg/mL ethidium bro-
mide, visualized with an ultraviolet transluminator UV
(Cole Parmer Instruments, Inc., Chicago, IL, USA) and
photographed.The photograph was digitized by using a
scanner (Lacie Silver Scanner for Macintosh) and the
Desk Scan software (Adobe PhotoShop) on a desktop
computer. The image was inverted before performing
densitometric analysis by using National Institutes of
Health Image 1.6 software (Wayne et al, Division of com-
puter Research and Technology, NIH, Bethesda, MD,
USA).
The NOS isoforms signals were standardized against b-
actin signal for each sample, and results were expressed
as each NOS isoform/b-actin ratio, respectively. The PCR
products of TGF-b and b-actin were also electrophoresed
in the same gel and ratio for TGF-b /b-actin for each sam-
ple was determined.
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Autoradiography for angiotensin II receptors
A total of 20 rats were used for radioligand binding
studies. Immediately after the animals were killed, kid-
neys from control and unilaterally obstructed animals be-
fore and after losartan treatment were removed, weighed,
and frozen in isopentane. The kidneys were stored at –
70◦C. Tissues were used for autoradiography and within
2 weeks the animals were sacrificed. The kidneys placed
on dry ice and cut into 16 lm thick slices with the aid of
a cryostat. The sections were collected on gelatin-coated
microscope slides and kept on a dessicator overnight at
4◦C. The sections were incubated in vitro with 0.2 nmol/L
[125I] Sar-1, Ile-8 angiotensin II (Amersham Pharmacia
Biotech Code IM248, Buckinghamshire, UK), activity
2000 Ci/mmol, as described in previous work [28]. Briefly,
sections were preincubated during 15 minutes at room
temperature in 10 mmol/L sodium phosphate buffer, pH
= 7.4, containing 120 mmol/L NaCl, 5 mmol/L disodium
EDTA, 0.005% bacitracin (Sigma Chemical, Co.) and
0.2% BSA fraction V (Sigma Chemical Co.) followed by
an incubation for 120 minutes in fresh buffer containing
the ligand. After the incubation period, the slides were
rinsed four consecutive times, 1 minute each, in fresh ice-
cold 50 mmol/L Tris-HCl buffer, pH = 7.6, followed by
a 30-second rinse in ice-cold water and allowed to dry
overnight on a dessicator under vacuum. For angiotensin
II subtype identification, consecutive sections were incu-
bated with the ligand in the presence of 1 × 10−5 mol/L
of AT1 losartan (code MRL-459/4 donated by Roemmers
Laboratory), to define AT2 receptors, or 1 × 10−5 mol/L
PD123319 ditrifluoroacetate (Sigma Chemical Co.), to
define AT1 subtype. Nonspecific binding was defined by
incubating in the presence of 5 × 10−6 mol/L angiotensin
II acetate (Sigma Chemical Co.). The dried labeled sec-
tions were overlay to 3H-Hyperfilm (Amersham, Arling-
ton Heights, IL, USA) in x-ray cassettes. Together with
a set of 14C standard (Amersham Pharmacia Biotech),
films were developed with Kodak GBX developer and
fixer after 4 to 7 days’ exposure. Densitometric analy-
sis was performed by digitalization of the images and
curve fitting made with the aid of the NIH Image pro-
gram, 1.6/ppc. Values are expressed in fmol/mg protein
by using a correction factor that includes the equivalence
of milligram of plastic polymer of the standards with the
protein content in the tissue.
Immunoblotting analysis for COX-2
Renal cortex and medulla were homogenized in
50 mmol/L Tris-HCl (pH = 7.8) lysis buffer containing
0.01% Triton X-100 and protease inhibitor cocktail. Af-
ter that, the homogenates were centrifuged at 4◦C, 11,000
rpm, for 30 minutes. Protein concentrations of the result-
ing supernatants were determined by Lowry method by
using BSA as standard [29]. Forty micrograms of proteins
were mixed with 10 lL of sample buffer [125 mmol/L
Tris-HCl, pH = 6.8, 4% sodium dodecyl sulfate (SDS),
3.5 mmol/L DTT, 0.02% bromophenol blue and 20%
glycerol], boiled for 2 to 3 minutes, and loaded into an 8%
SDS-polyacrylamide gel elctrophoresis (PAGE) gel. Pro-
tein molecular mass markers were always loaded on each
gel. The protein bands were transferred into a polyviny-
lidine difluoride (PVDF) membranes (Polyscreen NEF
1000), which were purchased from NEN Life Science
Products using a blot transfer system (Bio-Rad Labo-
ratories). After being blocked with 5% BSA and Tris-
buffered saline (TBS) solution (20 mmol/L Tris and
500 mmol/L NaCl, pH = 7.5) overnight, at 4◦C with gen-
tle agitation, membranes were incubated with a primary
rabbit anti-COX-2 polyclonal antibody solution (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) (1:1000 dilu-
tion) for 1 hour at room temperature. After washing three
times with TTBS (0.1% Tween 20, 100 mmol/L Tris-HCl,
pH = 7.5, and 150 mmol/L NaCl), membranes were incu-
bated with an antirabbit IgG secondary antibody linked
to biotin for 1 hour at room temperature [30]. Membranes
were washed twice and the color was developed by using
a Vectastain ABC 8211detection system.
After exposure to x-ray film, the photograph was dig-
itized using a scanner (Lacie Silver Scanner for Macin-
tosh) and the Desk Scan software (Adobe PhotoShop)
on a desktop computer as previously described.
Statistical analysis
The results were assessed by one-way analysis of vari-
ance (ANOVA) for comparisons among groups. Signif-
icance of differences was estimated by Bonferroni test.
A P < 0.05 was considered to be significant. Student
t test was performed to compare the means when the
experimental design consisted of two samples. Statistical
significance was assessed by Student impaired t test.
A P < 0.05 was considered to be significant. Results are
given as means ± SEM. Statistical tests were performed
by using GraphPad In-Stat, version 3.00, for Windows 95
(GraphPad Software, Inc., San Diego, CA, USA).
RESULTS
Oral administration of losartan during 15 days had no
effect on blood pressure in obstructed and control rats
(111.9 ± 2.2 mm Hg vs. 110.4 ± 2.2 mm Hg, and 110.4 ±
2.2 mm Hg vs. 112.7 ± 3.2 mm Hg, respectively). Body
and kidney weights were similar among groups. Data are
included in Table 1.
To assess the effect of losartan on renal function, we
performed renal clearance studies in each of the kidneys
of six rats of the four groups. Table 1 shows that glomeru-
lar filtration rate (GFR) was intensively decreased in the
post-obstructed kidneys of vehicle-treated animals com-
pared with sham-operated rats (P < 0.001). Recovery of
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Table 1. Blood pressure, body weight, kidney weight, and glomerular filtration rate (GFR) in unilateral ureteral obstruction (effect of AT1
angiotensin II receptor inhibition)
Group I Group III
Group II Group IV
Obstructed Contralateral Control Obstructed Contralateral Control
Parameters kidney kidney kidney kidney kidney kidney
Weight g 195.80 ± 3.20 194.60 ± 4.30 195.40 ± 4.00 196.80 ± 5.00
Kidney weight mg 590 ± 31.20 547 ± 7.30 520.30 ± 10.50 580.80 ± 17.20 540.40 ± 30.30 525.50 ± 10.30
Blood pressure mmHg 94.80 ± 2.60 97.70 ± 3.40 96 ± 0.60 98.60 ± 2.88
GFR mL/min 0.25 ± 0.05a 1.22 ± 0.10 0.90 ± 0.08 0.592 ± 0.06 1.09 ± 0.06 0.88 ± 0.06
Groups I and II, Unilateral ureteral obstructed rats and control rats without Losartan treatment; groups, III and IV, Unilateral ureteral obstructed rats and control
rats pretreated with Losartan (oral dose of 10 mg/kg) for 15 days.
Values are means ± SEM.
aP < 0.01 GFR in postobstructed kidneys without losartan (N = 6) vs. GFR in control kidneys (N = 6).
Where in table P < 0.05 GFR in postobstructed kidneys without losartan vs. GFR in postobstructed kidneys with losartan (N = 6).
A B C
FED
Fig. 1. Trichromic-Masson stained sections of rat kidney cortex and medulla. (A) Sham-operated kidney cortex. (B) Ureter-obstructed untreated
kidney cortex. (C) Ureter-obstructed, losartan-treated kidney cortex. (D) Sham-operated kidney medulla. (E) Ureter-obstructed untreated kidney
medulla. (F) Ureter-obstructed, losartan-treated kidney medulla (magnification 400×).
GFR was observed in losartan-treated group with ob-
struction (P < 0.05). The GFR of the contralateral kid-
neys tended to be increased in the losartan-treated group
similar to that of the vehicle group, compared with the
sham one. No significant differences on MAP were ob-
served among groups (Table 1).
Morphology of the renal cortex and medulla
We analyzed the degree of tubulointerstitial fibrosis af-
ter 24 hours of UUO in cortical and medullary sections
of rat kidneys subjected to the treatment with vehicle or
losartan, as described in the Methods section. Masson’s
trichrome-stained sections were used to analyze the ac-
cumulation of collagen in the interstitium. With this stain,
collagen was colored blue. Collagen was detected in Bow-
man’s capsule, in the basement membrane surrounding
tubules in mesangial matrix, and in capillaries of control
kidneys, as it has been previously shown [21]. In compar-
ison, kidneys subjected to UUO for 24 hours had higher
accumulation of collagen in the expanded interstitium
along with cellular interstitial infiltrates in the cortex and
medulla. Contralateral, nonligated kidneys in all of the
experimental groups were indistinguishable from normal
kidneys. Kidneys from rats treated with losartan for 15
days before the obstruction surgery had less interstitial
collagen deposition compared to kidneys subjected to
UUO (Fig. 1).
Morphometric analysis of tubulointerstitial volume
The volume of the interstitial fibrotic area relative to
the cortical tubulointerstitial area was expressed as the
volume fraction (Vv). The interstitial volume of the ob-
structed cortex kidney revealed a twofold expansion of
the interstitial space compared to control, from 13.7 ± 1.5
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to 28 ± 2.6 (P < 0.01) of the cortical volume. In the group
of rats given losartan before unilateral obstruction, the
expansion of the interstitial space was significantly de-
creased 28 ± 2.6 vs. 20.7 ± 1.2 (P < 0.01). Increased
interstitial volume fraction (Vv) was also demonstrated
in obstructed medulla compared to control medulla
32 ± 3.8 vs. 5.5 ± 1.8 (P < 0.01). After losartan administra-
tion, lower volume fraction (Vv) was shown in obstructed
kidney medulla 32 ± 3.8 vs. 19 ± 2.7 (P < 0.01). No signif-
icant difference was observed in Vv of the contralateral
cortex and medulla kidneys from groups I and III related
to control.
Tubular diameter in renal cortex and medulla
Determination of tubule diameter was carried on from
the same sections in which interstitial volume was mea-
sured. The average tubule diameter in sections of ob-
structed cortex kidneys (N = 6) was similar to that of the
kidneys of the sham group 21.4 ± 4 lm vs. 21.2 ± 2 lm.
No tubular atrophy was demonstrated in obstructed kid-
neys. Slight increase in tubular diameter was found in
obstructed medullas related to control 22.1 ± 4 lm vs.
17.1 ± 2 lm (P < 0.05). Losartan induced no changes on
tubular diameter on obstructed cortex 21.4 ± 4 lm vs.
22.5 ± 4 lm and medulla 22.1 ± 4 lm vs. 20.5 ± 1.2 lm,
respectively.
NOS activity on renal medulla tissue in obstruction:
Effect of losartan
NOS activity was measured by the conversion of L-[3H]
arginine to L-[3H] citrulline. When homogenates from re-
nal medulla tissue of obstructed kidneys without losar-
tan (group I, N = 10) were incubated in the presence
of saturating concentrations of the enzyme cofactors, a
significant increase in the activity of calcium/calmodulin-
independent NOS (iNOS) when compared to contralat-
eral kidney (0.675 ± 0.04 fmol [3H] citrulline/min/lg
protein vs. 0.237 ± 0.04 fmol [3H] citrulline/min/lg pro-
tein) (P < 0.001) and control kidney (group II, N =
10) (0.675 ± 0.04 fmol [3H] citrulline/min/lg protein
vs. 0.313 ± 0.01 fmol [3H] citrulline/min/lg protein)
(P < 0.001) was demonstrated. Although an increase
on calcium/calmodulin-dependent NOS (cNOS) activity
(fmol [3H] citrulline/min/lg protein) was observed in ob-
structed medulla related to medulla of control kidneys
without losartan (group II) (0.381 ± 0.03 vs. 0.198 ± 0.03)
(P < 0.01), higher iNOS activity in comparison to cNOS
activity was shown on the obstructed medulla 0.675 ±
0.04 vs. 0.381 ± 0.03 (P < 0.001) (Fig. 2).
Slight increase was observed on calcium/calmodulin-
dependent NOS activity in the medulla of the ob-
structed rat kidney without losartan (group I) compared
to medulla of contralateral kidneys (0.381 ± 0.03 fmol
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Fig. 2. Effect of oral losartan 10 mg/kg on nitric oxide synthase (NOS)
activity in rat renal medulla. (A) Calcium/calmodulin NOS activity
in obstructed kidneys (OKs) (N = 10) in animals of groups I and II
(without losartan treatment) related to control kidneys (CKs) (N = 10;
∗∗∗P < 0.001) and contralateral kidneys (CLKs) (N = 10; ∗∗∗P < 0.001)
for independent inducible NOS activity (iNOS), and for dependent con-
stituitive NOS activity (cNOS) in obstructed kidneys (N = 10) related
to control kidneys (N = 10; ∗∗∗P < 0.001) and contralateral kidneys
(N = 10 ∗P < 0.05). Higher iNOS activity related to cNOS activity
(∗∗∗P < 0.001) on the obstructed medulla without losartan [one-way
analysis of variance (ANOVA) test]. Values are means ± SEM. (B)
Calcium/calmodulin NOS activity (iNOS and cNOS) in obstructed kid-
neyss, contralateral kidneys, and control kidneys (N = 10) after losartan
administration. Decrease on calcium/calmodulin-independent (iNOS)
and dependent NOS (cNOS) activity in obstructed kidneys (N = 10)
after losartan administration related to the activity on obstructed kid-
neys without losartan (N = 10; ∗∗∗P < 0.001), respectively. Group III
vs. group I (Student impaired t test). Values are means ± SEM.
[3H] citrulline/min/lg protein vs. 0.240 ± 0.02 fmol [3H]
citrulline/min/lg protein) (P < 0.05) (Fig. 2).
Homogenates from renal medulla tissue of obstructed
kidneys with Losartan (group III, N = 10) induced a
decrease of iNOS activity when compared to medulla
of obstructed kidneys without losartan (0.190 ± 0.02
fmol [3H] citrulline/min/lg protein vs. 0.675 ± 0.04 fmol
[3H] citrulline/min/lg protein) (P < 0.01). Decrease on
calcium/calmodulin-dependent NOS activity was also ob-
served in the renal medulla of obstructed kidney with
losartan (group III) related to the renal medulla of ob-
structed kidney without losartan (group I) (0.133 ± 0.03
fmol [3H] citrulline/min/lg protein vs. 0.381 ± 0.03 fmol
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[3H] citrulline/min/lg protein) (P < 0.01). No differences
in homogenates of the renal medulla of contralateral kid-
neys with losartan (group III) compared to the one of the
medulla of contralateral kidneys without losartan (group
I) were observed in calcium/calmodulin-independent ac-
tivity (0.243 ± 0.02 fmol [3H] citrulline/min/lg pro-
tein vs. 0.237 ± 0.04 fmol [3H] citrulline/min/lg pro-
tein and calcium/calmodulin-dependent NOS activity
(0.190 ± 0.01 fmol [3H] citrulline/min/lg protein vs.
0.240 ± 0.04 fmol [3H] citrulline/min/lg protein). Mea-
surement of calcium/calmodulin-independent NOS activ-
ity (fmol [3H] citrulline/min/lg protein) on homogenates
of the renal medulla of control kidneys with losartan
(group IV, N = 10) showed a decreased activity com-
pared to control kidney medullas without losartan, group
II (0.137 ± 0.01 vs. 0.313 ± 0.01 (P < 0.01), no differ-
ences were observed on contralateral medulla pretreated
with losartan related to nontreated contralateral kidney
0.111 ± 0.01 fmol [3H] citrulline/min/lg protein vs.
0.198 ± 0.03 fmol [3H] citrulline/min/lg protein (Fig. 2).
NOS activity on renal cortex tissue in obstruction:
Effect of losartan
No differences were observed on calcium/calmodulin-
independent NOS activity among renal cortex of
obstructed, contralateral, and control kidneys without
losartan (groups I and II) 0.221 ± 0.02 vs. 0.235 ± 0.02 vs.
0.224 ± 0.01 (fmol [3H] citrulline/min/lg protein).
Homogenates of renal cortex of obstructed kidneys
without losartan (group I) showed a slight increase
on calcium/calmodulin-dependent NOS (cNOS) activ-
ity (fmol [3H] citrulline/min/lg protein), when compared
with renal cortex of control kidneys without losartan,
group II (0.396 ± 0.08 vs. 0.191 ± 0.03) (P < 0.01) and
contralateral kidneys without losartan (0.396 ± 0.08 vs.
0.194 ± 0.03) (P < 0.01). Higher cNOS activity compared
to iNOS activity in obstructed kidney was shown (P <
0.05) (Fig. 3).
After losartan administration, no differences were ob-
served on calcium/calmodulin-independent NOS activity
related to obstructed kidney without losartan: iNOS 0.225
± 0.03 fmol [3H] citrulline/min/lg protein vs. 0.221 ±
0.02 fmol [3H] citrulline/min/lg protein. On the contrary,
decreased activity was observed on calcium/calmodulin-
dependent activity in obstructed cortex after losartan
compared to nontreated obstructed cortex 0.160 ± 0.04
fmol [3H] citrulline/min/lg protein vs. 0.396 ± 0.08 fmol
[3H] citrulline/min/lg protein (P < 0.001). No differences
were observed on calcium/calmodulin-independent and
dependent NOS activity in contralateral and control kid-
neys after the administration of losartan for 15 days,
before unilateral obstruction for 24 hours compared to
basal conditions contralateral cortex, iNOS 0.207 ± 0.02
fmol [3H] citrulline/min/lg protein vs. 0.235 ± 0.02 fmol
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Fig. 3. Effect of oral losartan 10 mg/kg on nitric oxide synthase (NOS)
activity in rat renal cortex. (A) Calcium/calmodulin-independent in-
ducible NOS activity (iNOS) in obstructed kidneys (OKs) (N = 10),
control kidneys (CKs) (N = 10), and contralateral kidneys (CLKs)
(N = 10) without losartan administration. Increased calcium/
calmodulin-dependent constituitive NOS activity (cNOS) in obstructed
kidneys (N = 10) related to control kidneys (N = 10; ∗∗P < 0.01)
and contralateral kidneys (N = 10; ∗∗P < 0.01). Groups I and
II [one-way analysis of variance (ANOVA) test]. (B) Decrease on
calcium/calmodulin-dependent NOS activity in obstructed kidneys
(N = 10) after losartan administration related to the activity in ob-
structed kidneys nonlosartan treated (N = 10; ∗∗∗P < 0.001). Group III
vs. group I (Student impaired t test). Values are means ± SEM.
[3H] citrulline/min/lg protein; cNOS 0.184 ± 0.02 fmol
[3H] citrulline/min/lg protein vs. 0.194 ± 0.03 fmol [3H]
citrulline/min/lg protein groups I and III; control cortex,
iNOS 0.145 ± 0.02 fmol [3H] citrulline/min/lg protein vs.
0.224 ± 0.01 fmol [3H] citrulline/min/lg protein; cNOS
0.153 ± 0.003 fmol [3H] citrulline/min/lg protein vs.
0.191 ± 0.03 fmol [3H] citrulline/min/lg protein, groups
II and IV (Fig. 3).
NOS mRNA isoforms expression on renal medulla
in obstruction
Under identical conditions, an amount of 3 to 5 lg
of total RNA from each renal medulla of obstructed,
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contralateral and control kidneys was reverse tran-
scribed. The integrated optical intensity of the RT-PCR
product of iNOS, nNOS, and eNOS isoforms fluorescence
in the ethidium bromide stain was analyzed. The inten-
sity of the amplified housekeeping gene, b-actin was al-
most uniform in all tissues, confirming that the efficiency
of RT did not vary significantly between samples. The
amplified fragment of iNOS (222 bp) was clearly visible
in obstructed medulla iNOS expression. Slight detection
was demonstrated in contralateral and control medulla.
Densitometric analysis of the iNOS mRNA corrected for
b-actin expression (relative densitometric units) showed
a significant increase on obstructed medulla compared to
contralateral kidney 0.852 ± 0.05 vs. 0.614 ± 0.04 (P <
0.05) and control kidney 0.852 ± 0.05 vs. 0.538 ± 0.06 (P <
0.01). Decrease on iNOS mRNA expression was demon-
strated in obstructed medulla kidneys pretreated with the
inhibitor of AT1 receptor of angiotensin II (group III),
compared to iNOS mRNA expression in obstructed kid-
neys without losartan (group I) with a significant lower
densitometric ratio iNOS mRNA to b-actin (relative den-
sitometric units) 0.852 ± 0.01 vs. 0.646 ± 0.04 (P < 0.05)
(Fig. 4).
On the contrary, no differences were observed on the
analysis of the nNOS mRNA corrected for b-actin ex-
pression on medulla among groups, with a densitometric
ratio (relative densitometric units) of nNOS in obstructed
kidney 0.714 ± 0.02, contralateral kidney 0.680 ± 0.03,
and control kidney 0.672 ± 0.03, respectively (groups I
and II).
In obstructed kidney medullas, after losartan, de-
creased nNOS expression was shown 0.714 ± 0.02 vs.
0.530 ± 0.01 (P < 0.01).
There were no changes on iNOS and nNOS signal
standardized against b-actin signal (relative densitomet-
ric units) for each sample in contralateral medulla after
losartan administration, iNOS 0.614 ± 0.08 vs. 0.600 ±
0.01, and nNOS 0.630 ± 0.03 vs. 0.680 ± 0.03. Similar re-
sults were obtained in the expression of iNOS in control
medulla after losartan 0.538 ± 0.10 vs. 0.521 ± 0.009, de-
creased nNOS expression was shown on control medulla
after AT1 receptor inhibitor 0.672 ± 0.034 vs. 0.510 ± 0.08
(P < 0.05) (groups II and IV).
Densitometric analysis of the eNOS mRNA corrected
for b-actin expression (relative densitometric units)
showed a significant increase on obstructed medulla com-
pared to control kidney 1.10 ± 0.07 vs. 0.730 ± 0.02
(P < 0.01). No difference expression of eNOS was ob-
served on contralateral medulla compared to obstructed
medulla 1.27 ± 0.03 vs. 1.10 ± 0.02. After losartan ad-
ministration no differences were observed on eNOS ex-
pression in medulla of obstructed kidney 1.10 ± 0.07 vs.
1.24 ± 0.0, contralateral medulla 0.730 ± 0.02 vs. 0.750
± 0.02, and control medulla 1.27 ± 0.03 vs. 1.28 ± 0.04
(Fig. 6A).
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Fig. 4. Expression of inducible nitric oxide synthase (iNOS) and b-actin
mRNA in kidney medulla after unilateral ureteral obstruction (UUO).
(A) Representative gel of iNOS mRNA in medulla obtained from con-
trol (lane A),contralateral (lane C), and obstructed kidney (lane E) 24
hours following UUO. After AT1 angiotensin II receptor blockade by
inhibitor losartan products of reverse transcription-polymerase chain
reaction (RT-PCR) for iNOS are shown in lane B (control medulla),
lane D (contralateral medulla), and lane F (obstructed medulla). House-
keeping gene b-actin expression is included in below the iNOS ex-
pression. These results are typical of six independent observations. (B)
Semiquantitative PCR analysis of iNOS isoform in renal medulla of
UUO, contralateral and control kidneys. Effect of losartan increased
iNOS/b-actin mRNA ratio in obstructed kidneys (OKs) (N = 6) re-
lated to control kidneys (CKs) (N = 6; ∗∗P < 0.01) and to contralateral
kidneys (CLKs) (∗P < 0.05). Increased iNOS/b-actin mRNA ratio in
obstructed kidneys (N = 6) related to obstructed kidneys with losartan
(Los) treatment (N = 6; ∗P < 0.05). Values are means ± SEM.
NOS mRNA isoforms expression on renal cortex
in obstruction
No differences on the densitometric analysis of iNOS
mRNA corrected for b-actin expression (relative densito-
metric units) in obstructed cortex related to contralateral
and control cortex were observed, 0.626 ± 0.06 vs. 0.695 ±
0.03 vs. 0.597 ± 0.04 (groups I and II). The pretreatment
with an inhibitor of AT1 angiotensin II receptor showed
no differences on the levels of iNOS signal in obstructed
kidneys, 0.658 ± 0.05 vs. 0.626 ± 0.06. No differences on
iNOS mRNA corrected for b-actin expression (relative
densitometric units) were shown after Losartan treat-
ment on control kidneys, 0.597 ± 0.047 vs. 0.532 ± 0.033
and contralateral kidneys, 0.695 ± 0.038 vs. 0.710 ± 0.016
(groups III and IV).
Cortical nNOS expression was increased in the ob-
structed kidney compared with control and with con-
tralateral kidney cortex 0.847 ± 0.03 vs. 0.720 ± 0.02 (P <
0.05) and 0.847 ± 0.03 vs. 0.680 ± 0.02 (P < 0.01) (groups I
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Fig. 5. Detection of neuronal nitric oxide synthase (nNOS) mRNA
and b-actin gene by reverse transcription-polymerase chain reaction
(RT-PCR) analysis in cortex of kidneys after unilateral ureteral ob-
struction (UUO). (A) Primers for nNOS (308 bp) were used in PCRs
with cDNAs synthesized from the indicated tissues. The PCR products
were analyzed on ethidium bromide–stained 1.5% agarose gels. Lane
A, control cortex; lane C, contralateral cortex; and lane E, obstructed
cortex. After treatment, lane B (control cortex) lane D (contralateral
cortex), and lane F (obstructed cortex). Housekeeping gene b-actin ex-
pression is shown in the lower line in the same order as the densitometry
bars. These results are one of six independent observations. (B) Semi-
quantitative PCR analysis of nNOS isoform in renal cortex of obstructed
and control kidneys. Effect of AT1 angiotensin II receptor antagonist,
losartan (Los). In the vertical axis the ratio for nNOS/b-actin mRNA
is shown. Increased nNOS/b-actin mRNA ratio in obstructed kidneys
(OKs) (N = 6) related to control kidneys (CKs) (N = 6; ∗P < 0.05) and
to contralateral kidneys (CLKs) (∗∗P < 0.01). nNOS/b-actin mRNA ra-
tio in renal cortex after losartan administration in obstructed kidney vs,
nontreated obstructed kidneys (N = 6; ∗∗P < 0.01). Values are means
± SEM.
and II) (Fig. 5). Decreased cortical nNOS expression was
shown in obstructed kidneys after losartan administration
0.847 ± 0.03 vs. 0.589 ± 0.01 (P < 0.01). No changes on
nNOS signals were observed on contralateral pretreated
with losartan, nNOS 0.680 ± 0.020 vs. 0.630 ± 0.030
and on the control kidney cortexs after losartan, nNOS
0.720 ± 0.022 vs. 0.760 ± 0.030 (groups III and IV)
(Fig. 5).
The amplified fragment of eNOS (325 bp) was observed
in cortex of obstructed and contralateral kidneys,with less
expression in control kidney cortex (Fig. 6B). Densito-
metric analysis of eNOS mRNA expresssion showed a
significant increase in obstructed cortex related to control
1.30 ± 0.07 vs. 0.77 ± 0.03 (P < 0.001). Increase eNOS ex-
pression was observed in contralateral cortex vs. control
cortex 1.60 ± 0.030 vs. 0.77 ± 0.03 (P < 0.001), lesser in-
creased expression of eNOS was shown in contralateral
kidney compared to obstructed kidney 1.60 ± 0.030 vs.
1.30 ± 0.07 (P < 0.01).
Treatment with losartan induced no changes in eNOS
expression in obstructed cortex 1.30 ± 0.07 vs. 1.19 ± 0.02.
No differences on eNOS expression were observed after
losartan administration in control cortex and contralat-
eral cortex 0.77 ± 0.03 vs. 0.81 ± 0.03 and 1.60 ± 0.07 vs.
1.57 ± 0.02, respectively (Fig. 6B).
TGF-b mRNA expression on renal cortex kidney
in obstruction
We examined the expression of mRNA TGF-b in the
obstructed kidney cortex. As shown in Figure 7, UUO
induced an increased expression of TGF-b in obstructed
kidneys compared to control kidneys and contralateral
kidneys 0.839 ± 0.02 vs. 0.637 ± 0.03 (P < 0.05) and 0.839
± 0.02 vs. 0.650 ± 0.02 (P < 0.05), respectively. Adminis-
tration of losartan inhibited the induction of TGF-b , ob-
structed kidney 0.839 ± 0.02 vs. 0.666 ± 0.05 (P < 0.05).
Losartan induced no differences on TGF-b expression in
control and contralateral kidney cortexs 0.637 ± 0.03 vs.
0.625 ± 0.04 and 0.650 ± 0.02 vs. 0.670 ± 0.02, respectively
(Fig. 7).
COX-2 protein expression
The relative amount of COX-2 protein was determined
after normalization of the level of COX-2 protein of the
control kidneys without treatment. Immunoblot analysis
with an anti-COX-2 monoclonal antibody demonstrated
slight enhance levels of COX-2 protein expression in ob-
structed cortex, 1.18 ± 0.04 (P < 0.05) and intensive in-
creased protein expression in obstructed medulla 2.23 ±
0.03 (P < 0.001) relative to that in control kidneys. In-
creased COX-2 levels were observed in contralateral
medulla relative to that of control medullas 2.22 ± 0.04
(P < 0.001).
On the contrary, down-regulation of COX-2 protein
expression was demonstrated after losartan treatment in
the obstructed cortex and obstructed medulla kidneys
0.83 ± 0.03 (P < 0.01) and 0.54 ± 0.04 (P < 0.001), respec-
tively. Decreased COX-2 levels were observed in control
medulla after losartan administration 0.50 ± 0.04 (P <
0.01).
COX-2 expression showed no differences on control
cortex and contralateral kidney cortex and medulla, after
losartan administration (Fig. 8).
Renal angiotensin II receptor binding
In kidneys, [125I] Sar-1, Ile-8 angiotensin II binding was
localized to the outer cortex and outer medullary regions.
In the obstructed and control kidney cortex, the radioli-
gand was localized in glomeruli, the subcapsular area,
and in the longitudinal bands traversing the inner stripe
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Fig. 6. Expression of endothelial nitric oxide synthase (eNOS) and
b-actin mRNA in kidney medulla after unilateral ureteral obstruction
(UUO). (A) Effect of losartan (Los). Polymerase chain reaction
(PCR) products of control medulla (lane A), contralateral medulla
(lane C), and obstructed medulla (lane E). After losartan treatment,
lane B (control medulla), lane D (contralateral medulla), and lane F
(obstructed medulla). Housekeeping gene b-actin expression is shown
in the lower line, in the same order as the densitometry bars. These
results are one of six independent observations. Semiquantitative PCR
analysis of eNOS isoform in renal medulla. Graphic representation of
eNOS/b-actin mRNA ratio shows increased expression in obstructed
medulla vs. control medulla (∗∗P < 0.01). eNOS/b-actin mRNA ratio
increase expression in contralateral medulla vs. control medulla was
shown (∗∗P < 0.01). Values are means ± SEM. (B) Expression of eNOS
and b-actin mRNA in kidney cortex after UUO. Effect of losartan.
Primers for eNOS (325 bp) were used in PCRs with cDNAs synthesized
from the indicated tissues. The PCR products were analyzed on ethid-
ium bromide–stained 1.5% agarose gels. Lane A, control cortex; lane C,
of the outer medulla, corresponding to medullary vas-
cular bundles and collecting ducts. Down-regulation of
AT1 receptors binding was shown in 24-hour unilateral
obstructed kidneys (Fig. 9). Incubation of kidney slices in
the presence of losartan markedly inhibited binding to the
outer cortex and inner stripe of the outer medulla in ob-
struction leaving the sites corresponding to AT2 receptor
expression (Fig. 10). The densitometric analysis (Fig. 10)
revealed a remarkable decrease of the binding to the AT1
receptor in the cortex of obstructed kidneys, remaining
only about 15% from the binding observed in the control
kidneys. The same trend was observed in the inner stripe
of the outer medulla. Decreased AT1 receptor binding
density was also observed in contralateral kidney, with a
percentage of 30% from control. Minimal binding den-
sity of AT1 receptors was detected in the papillary region
of experimental and control kidney groups.
Intense decrease on AT1 angiotensin II receptor bind-
ing was observed after losartan treatment (10 mg/kg, oral
dose) in cortex and in inner stripe of the outer medulla in
ipsilateral UUO related to control. No differences were
observed in cortex and in inner stripe of the outer medulla
in obstructed kidneys with losartan treatment compared
to nontreated obstructed kidney group of animals. Lower
AT1 angiotensin II receptor binding was also shown
in contralateral and control kidneys after oral losartan
treatment.
Minimal binding to AT2 receptor was shown to be con-
stant in all groups studied and administration of losartan
did not modify the number of AT2 receptors in any case.
DISCUSSION
The study we present here adds to previous finding
demonstrating that the AT1 angiotensin II receptor in-
hibitor losartan is capable of blunting the progression of
the fibrotic disease, improving renal architecture in ob-
struction. This effect, involving modulation of the expres-
sion of NOS isoforms and COX-2, is independent from
changes in blood pressure.
Enhanced expression of renin-angiotensin system
(RAS) genes, involved in the pathogenesis of interstitial
fibrosis, has been demonstrated in UUO [5]. Intrarenal
contralateral cortex; and lane E, obstructed cortex. After losartan treat-
ment, lane B (control cortex), lane D (contralateral cortex), and lane
F (obstructed cortex). The correspondying housekeeping b-actin is in-
cluded in below the eNOS expression. These results are one of six inde-
pendent observations. Semiquantitative PCR analysis of eNOS isoform
in renal cortex. Graphic representation of eNOS/b-actin mRNA ratio
shows increase expression in obstructed cortex vs. control cortex (∗∗∗P <
0.001). eNOS/b-actin mRNA ratio increase expression in contralateral
cortex vs. obstructed cortex (∗∗P < 0.01) and in contralateral cortex vs
control cortex (∗∗∗P < 0.001). Values are means ± SEM. Abbreviations
are: CK, control kidney; CLK, contralateral kidney; OK, obstructed
kidney.
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Fig. 7. Reverse transcription-polymerase chain reaction (RT-PCR)
analysis of transforming growth factor-b (TGF-b) and b-actin mRNA
in renal cortex, 24 hours after unilateral ureteral obstruction (UUO).
(A) Effect of losartan (Los). Aliquots of cDNA prepared from cortex
of obstructed (OK), contralateral (CLK), and control kidneys (CK)
were coamplified for 30 cycles with TGF-b–specific primers (294 bp)
and with b-actin–specific primers. The products were separated on 3%
agarose gels and visualized by ethidium bromide staining. Lane A, con-
trol cortex; lane C, contralateral cortex; and lane E, obstructed cortex.
After losartan treatment, lane B (control cortex), lane D (contralateral
cortex), and lane F (obstructed cortex). Housekeeping b-actin expres-
sion was shown in the lower line, below the TGF-b expression. The first
nonlettered lane represents the migration of 100 bp ladder of molecu-
lar weight standards from Promega (Madison, WI, USA). These results
are one of five independent observations. (B) Semiquantitative PCR
analysis of TGFb In the vertical axis the ratios are shown for TGF-
b/b-actin mRNA in renal cortex after losartan administration (N = 6;
∗P < 0.05 nontreated obstructed kidneys vs. control kidneys; ∗P < 0.05
nontreated obstructed kidneys vs contralateral kidneys; ∗P < 0.05 non-
treated obstructed kidneys vs. treated obstructed kidneys). Values are
means ± SEM.
concentrations of angiotensin II increase rapidly after the
onset of ureteral obstruction being an early event in the
damage cascade that lead to the accumulation of ECM
proteins and renal damage [31]. Most of the biologic ef-
fects of angiotensin II are transduced by the presence and
distribution of AT1 receptors. Accordingly, we showed
marked down-regulation of AT1 receptor binding in ob-
structed kidneys presumably as the result of the increased
intrarenal angiotensin II production, representing the ac-
tivation of a negative feedback loop response- as it has
been previously reported [32]. Renal fibrogenesis initia-
tion at a very early stage, 24 hours of ureteral obstruction,
was demonstrated throughout the expanded interstitium
with twofold increase of interstitial volume and increased
expression of TGF-b within the affected kidney. Consis-
tent with our results, a significant up-regulation of TGF-b
and its type 1 receptor expression in the kidneys 1 day
after obstruction have been reported in an earlier study
[33]. TGF-b plays an essential role in initiating epithelial-
mesenchyme transformation that leads to the accumu-
lation of matrix-producing myofibroblast cells [34]. The
profibrotic role of angiotensin II has been demonstrated
by the induction of TGF-b type I and type II receptors
and increased synthesis of TGF-b in fibroblasts, smooth
muscle cells, and renal mesangial cells [35]. No tubu-
lar atrophy was demonstrated in obstructed kidneys. An
increase in distal tubule compliance [36] and enhanced
intraluminal hydrostatic pressure could explain the di-
latation in obstructed medullary collecting duct segments
we have demonstrated.
Administration of a nonhypotensive dose of the AT1
angiotensin II receptor inhibitor losartan for 15 days be-
fore 24 hours of UUO in our study nearly produced
protection against tubulointerstitial fibrosis with TGF-b
mRNA expression in obstructed kidneys similar to con-
trols. Evaluation of histologic indexes showed that losar-
tan treatment significantly decreased the expansion of the
interstitium in the obstructed kidney with no differences
in the volume fraction (Vv) of the cortical intertitium be-
tween the obstructed kidney after losartan administration
and control kidneys.
Increased nitric oxide generation has been shown to
ameliorate interstitial fibrosis. Arginine, as a direct pre-
cursor to nitric oxide, and ACE inhibitors involved in
the augmentation of nitric oxide production by stimulat-
ing bradykinin [37] have been found to blunt the fibrosis
response in obstruction. Although the protective role of
nitric oxide has been studied, results, including its molecu-
lar source, are still in conflict. Target deletion of the iNOS
gene (iNOS−/−mice) have been demonstrated to exac-
erbate interstitial fibrosis [38]. On the contrary, results of
Huang et al [39] have shown fibrosis reduction involv-
ing cNOS isoforms for its modulation in knockout iNOS
mice. Inhibition of COX-2 reduces TGF-b expression,
resulting in decreased tubular damage and interstitial fi-
brosis in obstruction. There is mounting evidence for a
biologic relationship between prostanoid and nitric oxide
biosynthesis. Continuous production of these molecules
is involved in chronic inflammatory conditions [40]. En-
dogenous nitric oxide is necessary for sustained COX-2
expression and prostaglandin synthesis in macrophages
[41].
In the present study, an intensive increase of iNOS ac-
tivity and expression in obstructed renal medulla with
lesser iNOS activity and expression on obstructed cor-
tex were shown, as we have previously reported [42].
Early cellular events postobstruction, including renal in-
terstitial macrophage infiltration and angiotensin II up-
regulation inducing increase on cytokine expression and
activity, are involved in the iNOS isoform expression in
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Fig. 8. Effect of losartan on renal
cyclooxygenase-2 (COX-2) protein ex-
pression in vivo. Immunoblotting analysis
of COX-2 from cortex and medulla of rats
treated by losartan (10 mg/kg). Lanes A and
B, Control medulla and cortex; lanes C and D,
control medulla and cortex-losartan treated;
lanes E and F, obstructed medulla and
cortex; lanes G and H, obstructed medulla
and cortex-losartan-treated; lanes I and J,
contralateral medulla and cortex; lanes K and
L, contralateral medulla and cortex-losartan
treated. The first nonlettered lane represents
the protein standart (COX-2, 72 kD).
Densitometric analysis of COX-2 protein
abundance in unilateral ureteral obstruction
(UUO). Effect of losartan. Immunoblots
were quantified for COX-2 expression. The
relative amount of COX-2 protein was
determined after normalization of the level
of COX-2 protein of the appropriate control
without treatment to 1. (A) Renal cortex.
Nontreated obstructed kidneys (OKs) vs.
control kidneys (CKs) (∗P < 0.05, nontreated
obstructed kidneys vs. contralateral kidneys
(CLK); ∗∗P < 0.01, nontreated obstructed
kidneys vs. treated obstructed kidneys). (B)
Renal medulla of obstructed and control
kidneys. Effect of losartan. Nontreated ob-
structed kidneys vs. control kidneys (∗∗∗P <
0.001, nontreated obstructed kidneys vs.
treated obstructed kidneys; ∗∗P < 0.01,
control kidneys vs. treated control kidneys).
Data represent mean ± SEM from five
separate experiments.
obstruction [43, 44]. The lesser iNOS expression activ-
ity we have observed in the obstructed cortex could be
presumably related to the increased expression of TGF-
b and its role in inducing a negative modulation of the
iNOS expression. TGF-b reduces iNOS expression by de-
creasing iNOS mRNA stability and iNOS mRNA trans-
lation, while increasing degradation of iNOS protein [45].
On the contrary, twofold increased cNOS activity accom-
panied by an increased eNOS and nNOS mRNA was
demonstrated in obstructed renal cortex. Similar to our
results in renal kidney cortex from angiotensin II–infused
hypertensive rats, an experimental model of intrarenal
angiotensin II, increased cNOS activity and nNOS and
eNOS protein expression have been demonstrated [46].
The role of constitutive NOS mainly related to eNOS
isoform in ameliorating interstitial fibrosis could be sug-
gested due to our previous study [44] and from others
showing a significant role of increased eNOS for down-
regulating renal fibrosis [39], and loss of eNOS contribut-
ing to increased tubulointerstitial renal injury [47].
Early proteinuric diabetic nephropathy increased
eNOS renal expression with enhanced indices of renal
oxidative/nitrosative stress. Angiotensin receptor block-
ers decreased both renal NADPH oxidase and eNOS,
preventing the development of oxidative damage [48].
In our results of increased cNOS activity, enhanced
nNOS isoform expression was demonstrated in obstruc-
tion. A role to nNOS as a marker of renal injury can
be inferred through recent studies showing nNOS gen-
eration of reduced oxygen species, including superox-
ide O−2 and hydrogen peroxide (H2O2), in the absence
of L-arginine [49]. nNOS also exerts a counteracting
modulatory influence on TGF-mediated afferent arteri-
olar constriction [50]. Selective increase in renal vascular
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Fig. 9. Autoradiographic images of 125I-Sar1-Ile8-Angiotensin II binding to regions of the obstructed and control kidneys. Binding in the control (a)
and obstructed kidney (c) is located mainly to the longitudinal bands traversing the inner stripe of the outer medulla, corresponding to the medullary
vascular bundles and collecting duct in the outer medulla of the kidneys and to the glomeruli in the renal cortex in control (d) and obstructed kidney
(f ). Histology of hematoxylin-eosin stained regions from obstructed kidney medulla (b) and obstructed kidney cortex (e) (magnification 78.7×).
resistance elicited by intrarenal angiotensin II levels have
been demonstrated in obstruction.
The suggestion that macula densa nNOS regulates
renin release and tubuloglomerular feedback by the ac-
tivation of a second signaling system COX-2 has been
reported [51]. Because of the localization of both nNOS
and COX-2 in the cortical thick ascending limb of the
loop of Henle (TALH), nNOS might be involved in me-
diating an increased COX-2 expression [52]. We have
demonstrated high levels of COX-2 and nNOS expres-
sion, and these results allow us to suggest a close inter-
action between both, in modulating renal hemodynamics
in obstructed cortex. In the present study, GFR was sig-
nificantly reduced in obstructed kidney.Conversely, con-
tralateral kidney GFR tended to be increased compared
with the sham one. The abrupt and transient induction of
RNA and protein products encoded by growth c-fos and
c-myc genes, and later increased activity of related heat
shock protein 70 (HSP70) and cH-ras genes, may possibly
play a role in the initiation of the hypertrophic response,
24 hours following ureteral obstruction in contralateral
kidney [53].
In our study, after an oral dose of losartan, no blood
pressure–lowering effects were demonstrated; however,
an intense anti-inflammatory action was evident due to
the tubulointerstitial fibrosis protection. The intensive
displacement of the iodinated tracer from its receptor
demonstrated in cortex and inner stripe of the outer
medulla in ipsilateral UUO showed no significantly de-
creased on AT1 angiotensin II receptor binding after
losartan treatment.
According with our results, recent observations have
demonstrated that losartan elicits anti-inflammatory
properties via its EXP3179 metabolite by blocking COX-
2 -mRNA up-regulation, intracellular adhesion molecule
(ICAM) mRNA regulation and cyclooxygenase-
dependent thromboxane A2 and prostaglandin F2
generation in vitro independent of its blockade at the
AT1 receptor [54].
The in vivo effect of the AT1 receptor antagonist
losartan in our results showed decreased medulla iNOS
mRNA and nNOS mRNA expression, persistent expres-
sion of eNOS in cortex, and decreased cortex and medulla
COX-2 protein expression. These results allowed us to
suggest a direct intrarenal anti-inflammatory leading to
tubulointerstitial fibrosis protection throughout an inde-
pendent action of losartan, involving NOS isoforms and
COX-2, in obstruction.
The nonsuppressed angiotensin II levels, because of
the increased ACE activity, despite a very low amount
of renin mRNA, reported in contralateral related to con-
trol kidneys in unilateral obstruction [5] could probably
explain the similar COX-2 protein levels in contralat-
eral to obstructed kidneys. Medullary COX-2 protein
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Fig. 10. Autoradiography and densitometiric measurements. (A) (Up-
per panel) Autoradiography of [125I] Sar-1, Ile-8 angiotensin II binding
24 hours after unilateral ureteral obstruction (UUO). Control kidney
(CK), contralateral kidney (CLK), and left obstructed kidney (OK)
binding in presence of 1 × 10−5 mol/L PD123177 (AT1 receptors).
(Lower panel) In situ autoradiographic localization and identification
of angiotensin II receptor subtypes in obstructed kidney after UUO for
24 hours. Longitudinal sections of rat kidney were incubated with [125I]
Sar-1, Ile-8 angiotensin II. Abbreviations are: OK-Total, angiotensin
II binding occurred primarily in glomerular area and the inner stripe
of outer medulla; OK-PD, incubation in the presence of PD123177 1
× 10−5 mol/L (AT1 receptors); OK-Los, incubation in the presence
of losartan 1 × 10−5 mol/L (AT2 receptor expression) was markedly
lower than AT1 binding and confined to the glomerular and subcapsu-
lar area; OK-NS, nonspecific binding was defined by incubating kidney
slices in the presence of 5 × 10−6 mol/L angiotensin II acetate. (B)
Densitometric measurement of angiotensin II AT1 receptor binding in
UUO and control nontreated and losartan-treated kidneys. Binding to
angiotensin II type 1 (AT1) receptors, as determined by quantitative
autoradiography, are expressed as a percentage from control kidneys.
(Upper panel) Down-regulation of AT1 receptor binding in obstructed
renal cortex (N = 5) related to control. Decreased AT1 receptor binding
after losartan treatment. (Lower panel) Decreased AT1 receptor bind-
ing in obstructed renal inner stripe of outer medulla (N = 5) related
to control. As in cortex, decreased AT1 receptor density after losartan.
Kidney sections were incubated with [125I]Sar1lle8 angiotensin II (0.25
nmol/L) in the presence of 1 × 10−5 mol/L PD123319 to assess AT1
receptors.
expression has been demonstrated to be restricted to
interstitial cells, morphologically classified as fibroblasts
and macrophages. The resident interstitial cells play a role
in collagen production and interstitial fibrosis induction
[55]. We have shown down-regulation of COX-2 protein
expression in control medulla after losartan; involvement
of its antifibrotic effect could infer, however, absence of
morphometric changes were shown in controls.
Due to the increased inducible NOS activity in ob-
struction and to a previous support for a role of
iNOS-generating nitric oxide and its interaction with
superoxide for peroxynitrite, a potent oxidant [11],
evidence for oxidative stress condition involved in the fi-
brotic process may be inferred in obstruction. Moreover,
finding supporting the hypothesis that peroxynitrite is
an important modulator of cyclooxygenase activity in in-
flammatory cells has been reported [56]. This mechanism
provides an explanation for the enhancement of cellular
prostaglandin biosynthesis by nitric oxide. While it has
been assumed that ONOO− when nitric oxide generated
from NOS reacts with exogenous O2, it has been demon-
strated that cellular nNOS and iNOS isoforms generate
superoxide with secondary formation of ONOO− leading
to cellular injury [49–57].
Our results of losartan down-regulation of iNOS,
nNOS, and COX-2 with persistent levels of eNOS could
suggest a profibrotic role of iNOS and nNOS isoforms in
obstruction.
For the present results, we can conclude that at very
early time obstruction, losartan protect for the fibrosis
progression through out its anti-inflammatory effect, in-
dependent from changes on blood pressure. A modula-
tion of NOS isoforms and COX-2 by AT1 angiotensin
II receptors could be included in the fibrosis blunted in
obstruction. Our results underline the potential clinical
implication of the fibrosis prevention in obstruction.
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